Resbiotic

ResBiotic Develops Probiotic and Pharmaceutical Therapies to Mitigate Neutrophilic Inflammation Associated with MalnutritionResBiotic’s first product is a medical food targeting the gut-lung axis, developed by Dr. Lal’s Lung Microbiome Lab at UAB, with research supported by the expertise of the University's Microbiology Center, Lung Health Center, and Translational Research in Normal and Disordered Development (TReNDD) program. The proprietary probiotic blend has demonstrated the ability to reduce neutrophilic inflammation in individuals with chronic respiratory conditions. The company’s R&D pipeline also includes drugs targeting various chronic pulmonary diseases.